Genome-Wide Analysis of Histone H3 Lysine9 Modifications in Human Mesenchymal Stem Cell Osteogenic Differentiation by Tan, Jiang et al.
Genome-Wide Analysis of Histone H3 Lysine9
Modifications in Human Mesenchymal Stem Cell
Osteogenic Differentiation
Jiang Tan
1., Jun Lu
1., Wei Huang
2, Zhixiong Dong
1, Chenfei Kong
1, Lin Li
1, Lina Gao
1, Jianhua Guo
2*,
Baiqu Huang
1*
1The Key Laboratory of Molecular Epigenetics of Ministry of Education, Institute of Genetics and Cytology, Northeast Normal University, Changchun, People’s Republic of
China, 2The Key Laboratory for Applied Statistics of Ministry of Education, Institute of Mathematic and Statistic, Northeast Normal University, Changchun, People’s
Republic of China
Abstract
Mesenchymal stem cells (MSCs) possess self-renewal and multi-lineage differentiation potentials. It has been established
that epigenetic mechanisms such as histone modifications could be critical for determining the fate of stem cells. In this
study, full human genome promoter microarrays and expression microarrays were used to explore the roles of histone
modifications (H3K9Ac and H3K9Me2) upon the induction of MSC osteogenic differentiation. Our results revealed that the
enrichment of H3K9Ac was decreased globally at the gene promoters, whereas the number of promoters enriched with
H3K9Me2 was increased evidently upon osteogenic induction. By a combined analysis of data from both ChIP-on-chip and
expression microarrays, a number of differentially expressed genes regulated by H3K9Ac and/or H3K9Me2 were identified,
implicating their roles in several biological events, such as cell cycle withdraw and cytoskeleton reconstruction that were
essential to differentiation process. In addition, our results showed that the vitamin D receptor played a trans-repression
role via alternations of H3K9Ac and H3K9Me2 upon MSC osteogenic differentiation. Data from this study suggested that
gene activation and silencing controlled by changes of H3K9Ac and H3K9Me2, respectively, were crucial to MSC osteogenic
differentiation.
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Introduction
Embryonic stem (ES) cells are pluripotent cells derived from
blastocysts that can differentiate into almost all cell lineages in vivo
[1–3]. Since the use of ES cells in research as well as in
therapeutics is encumbered by ethical considerations, a great deal
of attention has been turned to the derivation of stem cells from
non-embryonic origins, which provide investigators with an
invaluable cell source to study cell and organ development [4,5].
Such stem cells have been identified in many organ tissues,
including hematopoietic, neural, gastrointestinal, epidermal,
hepatic and mesenchymal stem cells (MSCs) [6,7]. MSCs show
properties shared by embryonic stem cells; they have the self-
renewal potential and can differentiate into several cell lineages
including osteoblasts, chondrocytes, adipocytes and myoblasts [8].
MSCs have demonstrated efficacy in multiple types of cellular
therapeutic strategies, including applications in treating children
with osteogenesis imperfecta, hematopoietic recovery, and bone
tissue regeneration strategies [4,9]. In contrast to diverse and
growing information concerning MSCs and their uses in cell-based
strategies, the mechanisms governing MSC self-renewal and multi-
lineage differentiation are not well understood and remain an
active area of investigation [10,11].
Modification of nucleosomal core histones is thought to be a
prevalent epigenetic mechanism in eukaryotic gene regulation,
most likely through modulation of chromatin structure [12]. More
than two dozens of site-specific histone modifications have been
described [13,14], and the acetylation and methylation of lysine
residues in the tails of nucleosomal histones have been shown to
exert crucial influences on chromatin packaging and gene
expression [15,16]. In general, acetylation of Lysine9 of histone
H3 (H3K9) correlates with gene activation, whereas enrichment of
H3K9 methylation is associated with gene silencing [16]. There
are three distinctive methylation states of histone H3K9, i.e.,
mono-, di-, and tri-methylation [17]. The pericentric heterochro-
matin is enriched for trimethylated H3K9 (H3K9Me3), while
centromeric regions are enriched for the dimethylated H3K9
(H3K9Me2) [18,19]. The establishment of specific gene expression
patterns during stem cell differentiation is a result of subtly
elaborated control of activation/silencing of large numbers of
genes [20–23]. To date, the profiles of histone modifications
during stem cell differentiation process, which may be tightly
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extensively studied.
DNA microarray technology has made it possible to profile and
quantify the expression of thousands of genes simultaneously [24].
Although the major use of DNA microarrays has been for mRNA
expression profiling, there are other applications [25]. Recently, a
technical method for genomic mapping of histone modifications in
vivo has been developed, allowing researchers to obtain a broader
view of the distributions of histone modifications. This method,
known as ‘‘ChIP-on-chip’’, is based on chromatin immunopre-
cipitation (ChIP) assay, and identifies the enriched DNA fragments
by hybridizing to microarrays with probes corresponding to
genomic regions of interest [26–28].
The aim of this study was to investigate the effects of genomic
changes in H3K9Ac and H3K9Me2 modifications at gene
promoter regions upon human MSC osteogenic differentiation,
by employing strategies based on ChIP-on-chip and expression
microarray methods. By linking data from both ChIP-on-chip and
expression microarrays, a series of differentially expressed genes
regulated by changes of H3K9Ac and H3K9Me2 were identified.
Furthermore, we found these genes participated in several cellular
pathways and biological events that were essential to MSC
osteogenic differentiation. Overall, results from this study
represent the first global view of the functional relationships
between modifications of H3K9 and gene expression in human
MSC differentiation, and suggested that gene activation and
silencing controlled by changes of H3K9Ac and H3K9Me2,
respectively, may be crucial to MSC osteogenic differentiation.
Results
Induction of human MSC osteogenic differentiation
Mesenchymal stem cells (MSCs) were derived from human
bone marrow, and the MSCs of the fifth generation were induced
to osteogenic differentiation by adding osteogenic differentiation
medium, as previously described [10]. Under this condition,
calcium deposition was detected by von kossa staining at day 7
after osteogenic induction, and the calcium deposition level was
increased markedly after 21 days (Figure 1A). Moreover, a
significantly increased level of the alkaline phosphatase enzyme
(ALPL) was observed at day 7 of osteogenic induction, compared
with the control cultures (Figure 1B). Real-time RT-PCR analyses
showed that the expression of marker genes of MSC osteogenic
differentiation, i.e., ALPL and CBFA1, increased significantly,
whereas the marker gene NANOG representative of the stemness
of the cells was down-regulated at day 7 of osteogenic
differentiation induction (Figure 1C). Thus, day 7 of the induction
was determined the transit point of osteogenic differentiation onset
of MSCs under this experimental condition, and this time point
had been used throughout the study.
Generation of histone modification profiles at gene
promoter regions by using ChIP-on-chip
It has been known that the mammalian epigenome undergoes
global remodeling during early development [29], and high
acetylation of H3K9 correlates with euchromatin, whereas the
enrichment of H3K9Me2 is associated with heterochromatin in
centromeric regions [18,19]. We were then interested in addressing
whetherchangesofH3K9AcandH3K9Me2occurredduringMSC
osteogenic differentiation. Global levels of H3K9Ac and H3K9Me2
were assessed by western blotting and immunofluorescence, and we
found that the level of H3K9Ac was decreased globally (Figure 2A
and B), while the H3K9Me2 level was increased 7 days after
osteogenic differentiation (Figure 2A and B).
Since the ChIP-on-chip results revealed that both H3K9Ac and
H3K9Me2 were changed globally at day 7 of osteogenic
induction, we wanted to further examine the genome-wide
distributions of H3K9Ac and H3K9Me2 at gene promoter regions
upon MSC osteogenic differentiation. In this study, the ChIP-DSL
H20K promoter array (Aviva) was employed to generate H3K9Ac
and H3K9Me2 profiles of gene promoter regions before and after
MSC osteogenic differentiation. For the promoter array, each
probe corresponded to a proximal promoter region from +200 bp
to 2800 bp relative to the transcription start sites, which
contains.95% of known binding sites for transcription factors in
human. Before hybridization of the H20K promoter arrays,
control experiments were carried out to confirm the specificity and
efficiency of the antibody and ChIP assay (Figure S1). MSCs were
induced for osteogenesis for 7 days as previously described [10],
and ChIP-on-chip assays were performed with antibodies against
H3K9Ac and H3K9Me2 by co-hybridizing differentially labeled
ChIP-enriched and total input DNAs to human promoter arrays.
When we create an IP/Input log ratio density plot, the tail on the
right distribution of log IP/Input was asymmetric with a heavy tail
corresponding to enriched group [30]. The ChIP-on-chip data
revealed that the gene promoters enriched with H3K9Ac was
decreased slightly (Figure 3A), whereas the number of promoters
enriched with H3K9Me2 was increased evidently after osteogenic
induction (Figure 3A).
Moreover, by comparing the H3K9Ac and H3K9Me2 profiles
at gene promoter regions between day 0 and day 7 cells, 1932 and
3543 gene promoters were found to exhibit more than 2-fold
increased enrichments in H3K9Ac and H3K9Me2, respectively
(Figure 3B and Table S2). Meanwhile, the promoter regions of
2090 genes and 3658 genes were decreased more than 2 folds in
H3K9Ac and H3K9Me2 enrichments, respectively (Figure 3B and
Table S2).
Position weight matrix analysis of the promoter motifs of
genes regulated by H3K9 modifications upon osteogenic
differentiation
To characterize the gene promoters that displayed differential
enrichments of H3K9Ac and H3K9Me2 upon the differentiation
process, the position weight matrix (PWM) analysis of the
transcription factor binding sites was carried out. The promoter
sequences (from +200 bp to 2800 bp relative to the transcription
start sites) of these genes (Table S2) were uploaded to the Cis-
regulatory Element Annotation System (CEAS, http://ceas.cbi.
pku.edu.cn/). As the results, the motifs with top 10 quantity hits at
gene promoter regions were listed (Table 1, Table 2). Specifically,
it can be seen from the motif lists that a large number of vitamin D
receptor potential binding sites (VDREs) (Table 1, Table 2) were
detected at promoters of genes in H3K9Ac-decreased and
H3K9Me2-increased groups; however, few VDREs were found
in H3K9Ac-increased and H3K9Me2-decreased groups (Table 1,
Table 2). Therefore, we proposed that VDR may possibly play as a
regulator of deacetylation and dimethylation of H3K9 in MSC
differentiation.
To validate our hypothesis, CDC20 and CTNND2 (catenin-d)
were selected for real-time RT-PCR and ChIP assay validation,
which resulted in discovery of several potential VDREs in gene
promoter regions (Figure 4A and B). Moreover, both CDC20 and
CTNND2 exhibited more than 2 folds down-regulation upon the
differentiation process, as shown by the microarrays (Table S3).
Real-time RT-PCR demonstrated that VDR was up-regulated,
whereas CDC20 and CTNND2 were down-regulated in MSC
differentiation (Figure 4C). Also, real-time ChIP-PCR revealed
that the enrichment of VDR was increased at the promoter
H3K9 Modifications in MSC
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have led us to speculate that VDR played a trans-repression role in
MSC osteogenic differentiation.
Comparison of gene expression patterns with promoter
H3K9 modification profiles in MSC osteogenic
differentiation
It has been known that changes in H3K9Ac and H3K9Me2
modifications can influence the chromatin structure and affect gene
expression [31], and these epigenetic modifications in specific loci
could be critical for determining the fate of stem cells [20]. To
determine theeffectsof changes ofH3K9Acand H3K9Me2 at gene
promoter regions upon human MSC osteogenic differentiation, we
performed a gene expression microarray analysis. From the
expression microarray, we found that 1041 genes were up-regulated
and 866 genes were down-regulated (Table S3). And then, we
analyzed data from the ChIP-on-chip and that from expression
microarrays in combination, which involved approximate 14000
known genes. To determine the relationship between H3K9Ac/
Figure 1. Identification of human MSC osteogenic differentiation. (A) Detection of calcium deposition by von kossa staining from 0 day to
21 days. (B) Determination of early osteogenic marker alkaline phosphatase (ALP) activity by staining in undifferentiated MSCs (left), and MSCs 7 days
after osteogenic induction (right). (C) Detection of expression profiles of MSC osteogenesis marker genes at day 7 of osteogenic induction.
Osteogenic specific genes, ALPL and CBFA1, were up-regulated, whereas the stemness marker gene NANOG was down-regulated 7 days after
induction of osteogenic differentiation. Standard error bars of three individual experiments are indicated.
doi:10.1371/journal.pone.0006792.g001
H3K9 Modifications in MSC
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6792Figure 2. Dynamic modifications of H3K9 in MSC osteogenic differentiation. (A) Western blots comparing global acetylation and
dimethylation of H3K9 in undifferentiated and osteogenic differentiating MSCs. (B) Immunofluorescence analysis of H3K9Ac/H3K9Me2 in
undifferentiated and osteogenic differentiating MSCs. DNA was stained by DAPI (blue); H3K9Ac and H3K9me2 were detected by the second antibody
with Alexa 546 (red). The results indicated that the H3K9Ac level was decreased, whereas the H3K9Me2 level was increased remarkably 7 days after
osteogenic differentiation. Scale bar represents 30 mm.
doi:10.1371/journal.pone.0006792.g002
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performed. The results revealed that approximately 60% of the
expressed genes were enriched with H3K9Ac in their promoter
regions, while more than 70% of the under-expressed genes were
enriched with H3K9Me2 (Figure 5A). The Venn diagram showed
that 166 genes were down-regulated by deacetylation in H3K9 and
121 genes were up-regulated by hyperacetylation in H3K9; and
meanwhile 67 genes were down-regulated by increased dimethyla-
tion and 34 genes were up-regulated by decreased dimethylation in
H3K9 upon MSC osteogenic differentiation (Figure 5B).
To validate the results above, real-time RT-PCR and ChIP-
PCR were carried out for randomly selected genes that were
Figure 3. Genome-wide identification of the gene enriched with H3K9Ac and H3K9Me2 upon MSC osteogenic differentiation. (A)
When the normalized mean IP/Input log ratios are plotted as density histograms, two populations of loci are apparent: the left peak represents the
non-enriched DNA fragments and the peak at the right side corresponds to the enriched DNA fragments. (B) Venn diagrams of differential H3K9Ac
versus H3K9Me2 changed genes.
doi:10.1371/journal.pone.0006792.g003
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regions shown in microarrays. The results indicated that the real-
time PCR data correlated very well with that shown in the
promoter and expression microarrays (Figure S2 and Table S4).
Among the genes tested, we found that the stemness genes OCT4
and NANOG were down-regulated by deacetylation and
dimethylation of H3K9 at promoter regions (Figure 5C and D);
whereas the osteogenic specific genes OPG and ALPL were up-
regulated with acetylated and de-dimethylated H3K9 at their
promoters (Figure 5C and D).
Pathway ontology analysis
To further clarify the functional ontology and networks related
to dynamic changes of enrichments of H3K9Ac and H3K9Me2
upon MSC osteogenic differentiation, we searched for the pathway
association and connectivity between putative target genes, by
using the software of pathway miner of the ‘‘Bio-resource for
Array Gene System’’ (Biorag, http://www.biorag.org/). This
software exploits a highly comprehensive database established
from the literature to determine direct and indirect interactions
between genes of interest, thereby identifying cellular pathways
associated with a particular set of genes. GenBank accessions of
these genes (Table S4) were uploaded to pathway miner of Biorag,
and the gene lists and association network based on cellular and
regulatory pathway data were generated (Figure 6). The analysis
showed that differentially expressed genes regulated by changes of
H3K9Ac and/or H3K9Me2 were involved in a number of cellular
pathways as revealed from Kegg pathway database (Table S5).
Specifically, we found that genes down-regulated by changes of
H3K9Ac and H3K9Me2 at promoter regions upon MSC
osteogenic differentiation principally belonged to cell cycle
pathway, regulation of actin cytoskeleton pathway, and TGF-beta
signaling pathway, etc. (Table S5). In contrast, genes up-regulated
by changes of H3K9Ac and H3K9Me2 were primary distributed
to cytokine-cytokine receptor interaction, complement and
coagulation cascades and Jak-STAT signaling pathways (Table
S5). Additionally, a network was generated depicting the
functional relationships implicated in these pathways. Figure 6
illustrates such a network that centers largely on such genes as
THBS1, PITX2, ID1, RBL1 and INHBA involved in TGF-beta
signaling pathways, linking cell cycle, cell communication and
cytokine-cytokine receptor interaction pathways together.
Table 1. Top 10 motifs of promoters underwent changes in H3K9Ac.
H3K9Ac Increased H3K9Ac Decreased
Enriched Motif Hits p-value Enriched Motif Hits p-value
M00986.Churchill 3602 4.46E-245 M00448.Zic1 3268 2.23E-190
M00428.E2F-1 3129 2.05E-255 M00450.Zic3 3122 1.10E-134
M00716.ZF5 2807 0.00E+00 M00378.Pax-4 3120 2.06E-144
AP2alpha 2308 6.24E-187 AP2alpha 2958 0
M00803.E2F 2056 0 M00449.Zic2 2904 1.34E-115
M00333.ZF5 1818 3.14E-108 M00033.p300 2831 3.48E-92
M00470.AP-2gamma 1382 2.96E-119 M00961.VDR 2741 6.05E-97
M00431.E2F-1 1216 4.28E-112 M00098.Pax-2 2637 3.81E-134
M00008.Sp1 1192 4.68E-94 M00497.STAT3 2632 1.40E-102
Elk-1 1055 3.32067E-44 M00333.ZF5 2366 8.12E-304
doi:10.1371/journal.pone.0006792.t001
Table 2. Top 10 motifs of promoters underwent changes in H3K9Me2.
H3K9Me2 Increased H3K9Me2 Decreased
Enriched Motif Hits p-value Enriched Motif Hits p-value
M00378.Pax-4 5675 4.44E-264 M00448.Zic1 5805 3.38E-276
M00450.Zic3 5564 7.29E-223 M00450.Zic3 5767 1.61E-229
M00448.Zic1 5536 6.25E-254 M00378.Pax-4 5702 2.24E-234
M00961.VDR 4947 7.02E-170 AP2alpha 4969 0
AP2alpha 4879 0 M00497.STAT3 4749 5.43E-153
M00497.STAT3 4861 4.60E-202 M00098.Pax-2 4588 6.96E-172
M00098.Pax-2 4592 2.86E-200 M00008.Sp1 2439 1.25E-261
M00008.Sp1 2376 2.84E-261 M00723.GAGA 2170 1.37E-88
M00723.GAGA 2183 7.30E-105 Elk-1 2067 1.13E-115
Elk-1 2159 1.55E-154 M00446.Spz1 2043 5.86E-152
Enrichments of H3K9Ac and H3K9Me2 matrices in the promoter sequences (2800 to +200 relative to transcription start site) of target genes were analyzed by using the
cis-regulatory element annotation system (CEAS).
doi:10.1371/journal.pone.0006792.t002
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computational screening for the enriched motifs of vitamin D receptor binding regions (VDRE) with nucleotide bias shown using Weblogo (http://
weblogo.berkeley.edu/). (B) The potential VDR binding elements at the promoter regions of CDC20 and CTNND2. (C) Real-time RT-PCR data showing
that VDR was up-regulated, whereas CDC20 and CTNND2 were down-regulated 7 days after osteogenic induction. (D) Real-time ChIP-PCR indicating
that the enrichments of VDR and H3K9Me2 were increased in CDC20 and CTNND2 promoter regions, whereas H3K9Ac was decreased upon MSC
osteoblastic differentiation. Standard error bars of three individual experiments are indicated.
doi:10.1371/journal.pone.0006792.g004
H3K9 Modifications in MSC
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Recently, studies of the adult stem cells provide ample evidence
that chromatin remodeling functions in universal differentiation
events [32]. A prevailed view of development biology holds that
the commitment of primitive multi-potent cells to specific lineages
is mediated by key transcription factors that activate downstream
tissue-specific genes [32]. Nevertheless, latest evidence shows that
heterochromatin formation can also be an important mechanism
for lineage restriction during development. For instance, the tri-
methylation level of histone H3, lysine 9 (H3K9Me3) was shown to
be increased dramatically during C2C12 cell line myogenesis,
which subsequently led to a large-scale heterochromatin reorga-
nization [29,33]. And the researchers discovered that following
differentiation from the activated B cell stage, chromatin in plasma
cells became condensed as DAPI-dense facultative heterochroma-
tin [34]. It seems likely that formation of facultative heterochro-
matin during cell differentiation involves some of the silencing
mechanisms that affect gene expression. In this study, western blot
and immunofluorescence data demonstrated that H3K9Ac was
decreased and H3K9Me2 was increased globally upon MSC
osteogenic differentiation (Figure 2A and B). Moreover, ChIP-on-
chip data revealed that the number of genes with high acetylated
H3K9 promoters was decreased, whereas the number of genes
with high dimethylated H3K9 promoters was increased signifi-
cantly 7 days after osteogenic induction (Figure 3). There have
been indications that hypoacetylation of H3K9 and high
dimethylated H3K9 were associated with facultative heterochro-
matin assembly resulting in transcriptional suppression [19]. Thus,
our results imply that deacetylation and dimethylation of H3K9
may cause the formation of facultative heterochromatin at specific
gene promoter regions, which may be significant to MSC
osteogenic differentiation through some silencing mechanisms.
A noticeable point arising from this study has been that, by
investigating the characteristics of promoter sequences of genes
that underwent H3K9Ac or H3K9Me2 changes during MSC
osteogenic differentiation, large numbers of vitamin D receptor
elements (VDRE) were found at gene promoter regions in both
H3K9Ac-decreased and H3K9Me2-increased groups (Table 1,
Table 2), whereas few VDREs were found in H3K9Ac-increased
and H3K9Me2-decreased groups (Table 1, Table 2). These results
suggested that VDR may be a potential regulator for mediating
deacetylation and dimethylation of H3K9 at specific gene
promoter regions in MSC osteogenic differentiation. VDR is
known as a member of the nuclear receptor (NR) gene
superfamily, and acts as a ligand-inducible transcriptional factor
[35]. It has been known that VDR could induce osteogenic
differentiation through up-regulating bone-specific genes [36].
Nevertheless, several recent observations revealed that VDR could
also repress transcription of genes in a ligand-dependent manner
Figure 5. Comparative analyses of the data from gene expression patterns and from promoter H3K9 modification profiles. (A)
Hierarchical cluster analysis of the enrichments of H3K9Ac/H3K9Me2, and the data of gene expression upon MSC osteogenic differentiation. (B) Venn
diagrams of H3K9Ac-decreased genes versus H3K9Me2-increased genes in expression-down pool, and H3K9Ac- increased genes versus H3K9Me2-
decreased genes in expression-up pool. (C) Real-time RT-PCR verification of gene expression of OCT4, NANOG, OPG and ALPL. The relative expression
values were normalized against GAPDH. (D) Real-time ChIP-PCR verification of H3K9Ac and H3K9Me2 of promoter regions of OCT4, NANOG, OPG and
ALPL upon MSC osteogenic differentiation. Standard error bars of three individual experiments are indicated.
doi:10.1371/journal.pone.0006792.g005
H3K9 Modifications in MSC
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In this study, we found that VDR was up-regulated more than 2
folds, whereas CDC20 and CTNND2 were down-regulated
(Figure 4C) with deacetylated and dimethylated H3K9 at
promoter regions. Simultaneously, the enrichment of VDR at
promoter regions of CDC20 and CTNND2 were increased
evidently upon MSC osteogenic differentiation (Figure 4D).
CDC20 is known as a cell cycle regulator, and CTNND2 is
initially identified as a neural-specific protein [40,41]. The
suppression of genes mediated by VDR participated in cell cycle
arrest and the selective silencing of other lineage-specific gene in
MSC osteogenic differentiation. Based on these data, we propose
that VDR may possibly play dual roles in both trans-activation
and trans-repression in MSC osteogenic differentiation; however,
the potential trans-repression mechanisms in details were still not
clearly understood. Recently, a model of ligand-induced trans-
repression function of VDR was put forward [38,39], in which
ATP-dependent chromatin remodeling complex WINAC was
required for the ligand-bound vitamin D receptor (VDR)-
mediated trans-repression of the 25(OH)D3 1a-hydroxylase genes.
Accordingly, we speculate that this mechanism may potentially be
effective in our MSC differentiation system, and the detailed
mechanisms warrant further investigations.
In this study, we have exploited a pathway functional genomics
approach to gain entry into epigenetic-related network, and
attempted to bridge the gaps between genes, histone modifications
and MSC osteogenic differentiation. Our pathway ontology
analysis revealed that the differentially expressed genes that were
regulated by changes of H3K9Ac and/or H3K9Me2 modifica-
tions were involved in a number of cellular pathways. Specifically,
we demonstrated that genes down-regulated by deacetylation and
dimethylation of H3K9 were involved in cell cycle related
pathway, actin cytoskeleton regulation pathway (Table S5),
whereas genes up-regulated by changes of H3K9Ac and
H3K9Me2 were primary distributed to cytokine-cytokine receptor
interaction (Table S5). Several studies implicated that differenti-
ation of stem cells required the withdrawal from the cell cycle and
re-establishment of a program of gene expression leading to the
elaboration of a specialized phenotype [42–44]. Also, it was
reported that rapid disruption of the actin cytoskeleton altered the
Figure 6. An informational network of the genes regulated by H3K9Ac and H3K9Me2 upon MSC osteogenic differentiation. The
informational pathway networks were generated by using BioRag (http//:www.biorag.org). The most affected pathways are the cell cycle pathway
(cluster I), the cell communication (cluster II), the cytokine-cytokine receptor interaction (cluster III), the regulation of actin cytoskeleton (cluster IV),
and the TGF-beta signaling pathway (cluster V)
doi:10.1371/journal.pone.0006792.g006
H3K9 Modifications in MSC
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ation [45]. Moreover, cytokines function as a positive control for
switching stem cells from a self-renewal to a differentiation stage
[46]. These data are in accordance with our results, suggesting
that dynamic changes of H3K9 modifications participated in
regulation of biological events essential to MSC osteogenic
differentiation. In addition, we observed that the osteogenic
specific genes, OPG and ALPL, were activated by alternations of
H3K9Ac and H3K9Me2 at promoter regions, whereas the
stemness genes, OCT4 and NANOG, were trans-repressed by
changes of H3K9Ac and H3K9Me2 upon MSC osteogenic
differentiation (Figure 5C and D).
Furthermore, our work has also established a relationship
network of the pathways regulated by changes of H3K9Ac and
H3K9Me2 (Figure 6). One advantage of assessing gene-gene
interaction network is that the characterization of the pathways
can be based not only on the functions of target genes but also on
those interacting genes. From this network, we noticed that genes
involved in TGF-beta signaling pathway, such as THBS1, PITX2,
ID1, RBL1 and INHBA, were at the center of the network, linking
cell cycle, cell communication and cytokine-cytokine receptor
interaction pathways together (Figure 6). In addition, it has been
reported that TGF-beta-1 could inhibit MSC osteogenic differen-
tiation [7]. Therefore, we propose that the H3K9Ac- and
H3K9Me2-mediated gene silencing in TGF-beta signaling
pathway may play a crucial role in MSC osteogenic differentia-
tion. Besides, it is noted that these pathways in the network were
also connected with one another through particular genes
(Figure 6). The information presented above has provided us with
important clues for further investigations into the interactive
pathways as well as the functional and biological relevance of the
targets of acetylation and dimethylation of H3K9.
In summary, data included in this report have depicted a
genome-wide blueprint of H3K9Ac/H3K9Me2 modifications and
expression profiles for human MSC osteogenic differentiation.
Additional studies should yield further insights into the dynamics
and hierarchy of epigenetic regulation in MSC osteogenic
differentiation.
Materials and Methods
Ethics Statement
To obtain primary cultures, human bone marrow MSCs were
derived from iliac crest marrow aspirates of healthy donor. A
written consent for use of the bone marrow MSCs was presented
by the donor.
The permission to use human bone marrow mesenchymal stem
cells in this study was granted by Peking University Health Science
Center’s Ethical Committee.
Isolation, culture and osteogenic differentiation
induction of human bone marrow mesenchymal stem
cells
Ten mL bone marrow from the donor was diluted 1:2 with PBS
and loaded over 5 mL Histopaque (Sigma). Cells were harvested
from the interface after centrifugation at 2000 rpm for 20 min and
washed with PBS. Cells were re-suspended in Modified Eagle’s
Medium of Alpha (a-MEM, Gibco) containing 10% fetal bovine
serum (Hyclone), 100 U/mL of penicillin, 100 mg/mL streptomy-
cin and 2 mM L-glutamine, and plated in a flask at the density of
3610
5 cells/mL. Non-adherent cells were discarded after cultiva-
tion for 48 h. The adherent cells were washed twice and cultured
for 10–14 days until cell clones were formed. Cells were analyzed
by flow cytometry to confirm their identity of MSCs. Cells were
then plated at a density of 1610
5 cells/cm
2 on amniotic
membrane and expanded until 90% confluence [47].
Osteogenic differentiation medium was prepared by supple-
menting the growth medium with 50 mg/mL ascorbic acid,
1.5 mg/mL b-glycerophosphate (Sigma), and 10
28 M dexameth-
asone (Sigma). Growth and differentiation media were replaced
twice a week and ascorbic acid was added to the differentiation
medium every other day [10].
Alkaline phosphatase enzyme histochemistry and von
kossa Staining
To detect alkaline phosphatase activity, cells were stained with
1 mg/mL Fast Red
TR (Sigma-Aldrich) and 0.2 mg/mL napthol
AS-MX phosphate (Sigma-Aldrich), dissolved in 1 mL N, N-
dimethylformamide (Sigma-Aldrich) in 0.1 M Tris buffer at
pH 9.2, and then fixed in 4% paraformaldehyde.
Calcium deposition was identified by using the von kossa
staining technique by adding 1% silver nitrate at room
temperature for 60 min under strong light, followed by 2.5%
sodium thiosulphate for 5 min.
Analysis of expression microarray and quantitative real-
time RT-PCR
Total RNA was isolated from cells using the Trizol reagents
(Invitrogen). The human genome 70-mer oligonucleotide micro-
arrays were obtained from CapitalBio, and the hybridization was
done by the CapitalBio Company service Corporation (Beijing,
China). The microarrays were scanned on a GenePix Pro4.0
scanner (Axon Instrument). Statistical analyses were performed by
using the statistical software R; all the scripts that were used are
available on request, and a space- and intensity-dependent
normalization based on a LOWESS program was employed
[48]. For each tests and control samples, two hybridizations were
performed by using a reverse fluorescence strategy, and 1.8-fold
averaged over the two biological replicates was set for significant
change between differentiation and undifferentiating conditions of
MSCs. Additionally, a nominal p value threshold of,0.05 was
used to select differentially expressed genes for further analyses.
Briefly, as there is a reverse fluorescence strategy in expression
analysis, we firstly averaged the two ratio replicates after
LOWESS normalization, and then used a corrected method
provided by Chen et al [49] to quantify the significance of
observed differences in expression ratios. Different from Chen’s,
here we proposed a robust method to estimate the c value:
^ c c~ median
i~1,2,:::,n
ti{1 ðÞ
2
1zti
2 ðÞ
 ! "# 1=2
where ti is the ith gene expression ratio. Using the estimation of c,
the p value was calculated as follows: (T=R/G)
pvaluei
^
~Pr Twti,1orTvti,2 ðÞ ~
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^
z
ðti,2
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2
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, one of the
ti,1,ti,2was calculated by the observation, the other one had the
same density value and calculated through fT t ðÞ .
Microarray data reported in the manuscript is deposited to
Array-express, and the expression microarray accession number is
A-MEXP-1567 (in accordance with MIAME guidelines).
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dent cDNA samples were analyzed by using real-time RT-PCR on
an ABI PRISM7000 Sequence Detection System (Applied
Biosystems), and the GAPDH gene was used as the internal
reference for normalizing the variations in the quality and the
amount of total cDNA. The primer sequences are shown in Table
S1.
Antibodies and ChIP assays
Anti-acetylated H3K9 (07-352) and anti-dimethylated H3K9
(07-212) antibodies were purchased from Upstate Biotechnology.
Anti-VDR was obtained from Abcam (ab54387). Cells were
crosslinked with formaldehyde and subjected to chromatin
immunoprecipitation (ChIP) assay as previously described [50].
Briefly, 1610
6 cells were treated with 2% formaldehyde in IMDM
medium for 10 min at 37uC to crosslink protein-DNA. To stop the
reaction, glycine (125 mM final) was added. After washing 4 times
with cold PBS, cells were lysed by incubating in nucleus lysis
buffer. The lysate was sonicated with a UibraCell TM-130
sonicator. After centrifugation at 12000 rpm for 10 min, the
supernatant was diluted 1:10 in ChIP dilution buffer. The
chromatin solution was precleared with 50 mL of protein A-
agarose beads (Upstate Biotechnology). The soluble fraction was
collected and 5 mg of anti-acetyl-histone H3K9 (Upstate Biotech-
nology), anti-dimethyl-histone H3K9 (Upstate Biotechnology), and
anti-VDR (Sigma, F3165) antibodies were added. After immuno-
precipitation, the precipitated complexes were collected by adding
60 mL of protein A-agarose beads. After washing, freshly prepared
elution buffer (1%SDS, 0.1 M NaHCO3) were added, and the
crosslinking was reversed at 65uC for 4 h. DNA was recovered by
Proteinase K digestion, phenol/chloroform extraction, and
ethanol precipitation.
Real-time quantitative PCR was performed on an ABI
PRISM7000 Sequence Detection System (Applied Biosystems),
and the total input was used as the internal reference for
normalization. The primer sequences are shown in Table S1.
ChIP-DSL and ChIP-chip assays
For ChIP-DSL assays, both input (5% of total DNA) and IP
(antibody-enriched DNA) were randomly biotinylated by using a
kit (Vector Laboratories) according to the manufacturer’s
instructions. All the T7-linked oligonucleotides were kinased and
then mixed with all T3-linked oligonucleotides. For each reaction,
we used 0.1 pmol per oligonucleotide in a pool suspended in
10 mL of TE buffer. The procedures for oligonucleotide annealing,
solid phase selection, ligation and PCR amplification were as
described [51], except Taq ligase was used in place of T4 ligase to
improve ligation specificity. Input DNA was labeled with Alexa
Fluor 647 and the immunoprecipitated DNA with Cy3. PCR
products were mixed, denatured, and hybridized to the 40-mer
Hu20K array. Slides were scanned on the GenePix Pro4.0 (Axon
Instrument). The Hu20K array and the associated assay kit with
detailed instruction are commercially available from Aviva
Systems Biology [26,27].
ChIP-chip data analysis
Due to both experimental and technical variability, the signal
must be standardized for proper comparison among experiments.
This can be done using the stochastic part of log IP/Input
distributions corresponding to the regions in which there is no
binding [30]. The distribution of log IP/Input may be asymmetric
with a heavy tail on the right corresponding to enrich [30]. The
frequencies of loci with different IP signal intensities were modeled
using EM algorithm to separate loci into groups with enriched and
non-enriched [30]. The LOWESS program was used to measure
the variability between different ChIP-on-chip arrays[52,53]. For
identification of H3K9 targets that are differentially acetylated and
methylated between differentiation and undifferentiating condi-
tions of MSCs, 2-fold was set for the significant change of
H3K9Ac and H3K9Me2. Similarly, the nominal p value threshold
of,0.05 was also used to distinguish the modification changed
genes. Briefly, two channel image data ratio (Cy5/Cy3) were
normalized by LOWESS method, and the p value calculation was
implemented using the same method as in the expression analysis.
Microarray data reported in the manuscript is deposited to
array-express, ChIP-chip accession number E-MEXP-2134 (in
accordance with MIAME guidelines).
Promoter motif analysis
Promoter sequences (from 2800 to +200) of genes undergoing
changes of H3K9Ac and H3K9Me2 modifications in MSC
osteogenic differentiation were analyzed by using the Cis-
regulatory Element Annotation System (CEAS, http://ceas.cbi.
pku.edu.cn/) to search for enrichments of position weight matrices
(PWMs) of transcription factor-binding motif in TRANSFAC [54].
Pathway analysis
Gene ontology and pathway analysis were performed by using
pathway miner of the Bio-resource for Array Gene System (Biorag,
http://www.biorag.org/). GenBank accessions were uploaded to
Biorag, and the gene lists and association networks based on
cellular and regulatory pathway data were generated [55].
Supporting Information
Figure S1 (A) Verification of specificity of antibodies. ChIP was
performed with the antibodies specific for H3K9Ac and
H3K9Me2 and immuno-detected by western blot with the
antibody against H3 without reverse-linking. (B) Validation of
efficiency of traditional ChIP assay. The antibody specific to
H3K9Ac was used, and b-actin gene promoter region was set as a
positive controal.
Found at: doi:10.1371/journal.pone.0006792.s001 (0.30 MB TIF)
Figure S2 Validation of expressiomn microarray and ChIP-chip
data by real time PCR. (A) Real time RT-PCR verification of gene
regulated by changes of H3K9Ac and H3K9Me2 at promoter
regions upon MSC osteogenic differentiation. The relative
expression values were normalized against GAPDH. Real time
ChIP-PCR verification of H3K9Me2 (B) and H3K9Ac (C) at
promoter regions of the selected genes upon MSC osteogenic
differentiation. Standard error bars of three individual experi-
ments are indicated.
Found at: doi:10.1371/journal.pone.0006792.s002 (0.49 MB TIF)
Table S1 primers for real time PCR
Found at: doi:10.1371/journal.pone.0006792.s003 (0.02 MB
XLS)
Table S2 the genes with changes of H3K9 modifications
Found at: doi:10.1371/journal.pone.0006792.s004 (1.04 MB
XLS)
Table S3 differentially expressed genes
Found at: doi:10.1371/journal.pone.0006792.s005 (0.46 MB
XLS)
Table S4 the genes regulated by changes of H3K9 modificaions
Found at: doi:10.1371/journal.pone.0006792.s006 (0.17 MB
XLS)
H3K9 Modifications in MSC
PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6792Table S5 Pathway ontology classification of differentially
expressed genes regulated by H3K9Ac and H3K9Me2
Found at: doi:10.1371/journal.pone.0006792.s007 (0.18 MB
DOC)
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